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SERTRALINE DOSING IN DEPRESSED INPATIENTS
T o the Editor:
In a ret ro sp ective cha rt review of all psychi atric inpa t ients, a t th e University of T ex as
Harris County Psychi atric Cente r, 2+ pati ent s were started on se r t rali ne for tr ea t men t of th e ir
depressive sympto ms . The primary qu esti on to be answe re d by thi s cas e st ud y was th e dos e a t
whi ch th e majorit y of inpatient s respond to se rt ra line in a clinical se tt ing . There a re no known
reports conce rn ing th e dose a t whi ch most inpati ent s respond.
Pati ents wer e not included in thi s study unl ess se rtra line was prescrib ed as recomm ended
by th e manufacturer (Pfize r), i.e. , an initia l dos e of 50 mg with a weekl y increase of 50 mg if
clinica lly indi cat ed , up to a m aximum of 200 mg. Ther e wer e 2+ patient s ( 18 women , 6 men)
with a mean age of 35 .2 yea rs (range 17-58) . Twenty pati ent s had a diagn osis of major
depressive disorder, 10 of wh om had conco m ita n t psychotic sym pto ms . Three pa t ients had a
diagn osis of schi zophren ia or schizoa ffec t ive di sorder, and ano ther had bipo lar d isord er,
depressed ph ase. In addit ion to each patient rece iving se r t ra line , 16 of th e pat ien ts received
neu rol eptics and 20 were treat ed with ben zodi azepines,
Of th e 2+ pati ent s, 2 1 were treat ed wit h se rt ra line for grea te r th a n 5 days. Of these 21, 10
(+8%) res ponde d a t the initial 50 mg da ily dose, 8 (38 %) a t 100 mg dai ly, 2 ( 10%) a t 150 mg
daily, and I (5%) a t 200 mg da ily. A resp on se was defined as a sig nifican t improvement in th e
de press ion such that th e pat ient co uld be discharged fro m th e hospital. No rati ng scale s were
used . O ne patient was tak en off se rt ra line a fte r I day a nd a not her aft e r 5 days for wor sening
medi cal or psychi atric problems, which were not fe lt to be re la ted to sert ra lin e. A third patient
had se r t ra line di scontinued on day 5 for ur inary and fecal incon tinence , which was fclt to be a
side effect. Of th e 2 1 pati ents who were disch arged on ser t ra line, 3 com pla ined of sid e effects
wh ich included mild di zziness, mild to mod era te nau sea an d occasiona l d ry mo uth. Fift een
cha r ts had documentation indicating no side effects ; 3 char ts ha d no documen ta tion regarding
side effects .
In this retrospecti ve review, +8% of depressed inpati ent s responded a t th e initia l 50 mg
dail y dose, a nd 86% responded at 100 mg or less. Thompson e t a l in a co ntrolled dose esca la t ion
st udy report ed 59% of depressed out pa tients responded a t th e initial 50 mg sert ra line dos e (I ).
Doo gan a nd Ca illa rd (2) in a sim ila r design report ed th at 78% of depressed out pa tien ts
im proved on a m ean sertraline dos e of less th an 100 mg da ily. Optimum dose is best eva lua ted
in a fixed dos e tria l, sinc e dos e esca la t ion st udies usually favor high er doses as most effect ive.
To dat e, th ere have be en no cont ro lled fixed do se tria ls with se rt ra line . Our current result s
using a do se esca la ting regimen mu st be viewed with ca ut ion for this reason as well as others.
The retrosp ective nature of this review as well as the mix ed diagn osti c groups, concom itt an t
medi cation use, va riable len gth of hospit aliz ation and lack of standard ized assessme nt of
depressive sym ptoms are clear lim ita t ions of this rep or t. Further, t he apparent high response
rat e in our subjects and relatively benign side effec t pr ofile ma y be du e to lim ited cha rt
documenta ti on of opt imal ben efits a nd d rawbacks of me d ica t ion . Nonetheless, this a nec do ta l
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rep ort may provid e some clinical guide until well controlled, fixed dose prospective studi es are
reported.
Moya Griffin
Medi cal Studen t
Unive rs ity ofTexas-Hou st on, TX
Dh yanne Warner, Ph .D., M.D.*
Psychiat ry Resident
Stanford Medi cal Schoo l-Stanford , CA
Ce cilia Peabody, M.D.*
V.A. Hospit al-Inpa tien t Treatmen t Unit
Menlo Park, CA
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TARDIVE DYSKINESIA AND CLOZAPINE
T o The Editor :
We wish to rep ort a cas e of tardive dyskinesia th at has shown a rapid and d ramat ic
response to Cloza pine without incident of ser ious side effec ts.
Case Report: A.S. is an 80 yea r-old, widowed , white fem al e who had ca r ried a di agn osis of
chro nic sch izophre nia since 1964 and had sin ce th en tak en T ril afon , 8 mg b.i.d . wit h
satisfactory th erapeutic results.
As ea rly as 5 years prior to ad m ission, A.S. was see n to have probl em s with "blinking of her
eyes." Examination showed a left facial hemispasm th at would persist for severa l seconds
duration, som etimes up to 30 seconds . This was accom pa nied by a fine twitching about bot h
eye lids and both sid es of her mouth. Approxim ately 3 months pr ior to admission, she was seen
in clinic for un controllabl e eye blinking th at had worsen ed in th e preced ing 7 month s. No signs
of lip sm acking, tongu e rolling, or pill ro lling movements were no tic ed by her doct or. Her
family had noticed a sligh t trem or bilat erall y in her upper ext re m ities in addi t ion to her facial
movem en ts . A pr eliminary diagnosis of tardive dyskinesia was established and her T rilafon was
subse que n tly reduced to 4 mg b.i .d .. She was see n again three week s lat er withou t subsequen t
improvem ent , a nd her med ication s were discontinued. Her fam ily report ed that her auditory
hallucination s th en markedl y wor sen ed , and her th ou ght beca m e ext re me ly incoheren t. O ne
month lat er, she was again re-examined a nd found to have wors ening of her eye blinking and
facial grimacing. She was th en ad mitted to a psychi atric uni t for eva luat ion and a lte rnat ive
psychotropic th erapy.
*Two of th e above a uthors (DW, CP) hold sto ck in Pfizer Ph armaceuticals.
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Examination up on ad m ission reve a led per sist ent ab no rma l invo luntary movem ents.
These consis te d of exagge ra te d eye blinki ng bilat erally, unusua l ext re me grimacing, jaw
cle nching , occur ring at a frequen cy of a pproximately on ce per second , and variou s lingual
movem ents. A pill rolling tremor was a lso not ed in th e absence of other truncal a nd
upper/lower limb ext re m ity movements . A DISC US assessmen t a t that time reveal ed a sco re
of25.
On day 6 of adm issio n, she was star te d on clozapi ne, 25 mg b.i.d . The dose was
subse q ue n tly raised to 25 mg t.i .d. on d ay 7. H er signs of ta rd ive dyskinesia showed a
subseq uent dr a ma tic and rapid improvem ent in response to this medi cation . She was eval u-
a te d with th e DISC US on day II which revealed a score of 16. Th rough out th e remainder of
her stay, facial movem ents persist ed , a lt ho ug h to a lesser degree th an upon ad mission, a nd she
was subsequen tly d ischarge d on day 12 on clozapine, 25 mg b.i .d.
On follow-up 4 week s lat er, she was se en to have cont inuing involuntary movem ents. A
DI SC US assess me nt reveal ed a score of 13, with gri macing and blin king rem aining severe.
Auditory hallu cin ation s cont inue d, bu t to a lesser degree. Throughout her Clozapine tri al ,
wee kly hemato log ic moni toring rev ea led no signs of neut ropen ia .
D iscussion: Cu rrent es t imates of th e pr eval en ce of TO a mo ng pat ien ts tak ing neurolep tic
drugs is tho ug h t to be 20%; however, ra tes va ry among pa ti ent pop ulations, ce rta in subg ro ups
of elderly excee ding 50% ( 1,2,3). Co nve n tio na l neu rol eptics hav e a ll been implicat ed in ca us ing
drug-induced movem ent disorders (1,3,4), which are th ou ght to result fro m a ltered doparnin-
erg ic ac t ivity within th e basal ga ng lia (5) .
T his pat ient de mon strat ed a rapid a nd dra ma tic response to clozapine, her DISC US score
dropping fro m 25 to 16 within II days, a nd to 13 within one mo nth. Most of th e immediat e
improve me n t was seen in reducti on of ora l and lingu al movements; unfortunately, facial an d
eye movemen ts conti nued to re main severe. T here was no wor sening in a ny of th e DISC US
sca le it em s a t one month com pared to her initi al exam.
Lieb erman, e t a l. (3) sugges ts seve ra l possibl e explana t ions for th e effec t iveness of
clozapine in patients with TO. There may exist a suppressive (maskin g) effect, such as th at
see n with " classica l" neu roleptics. However , th er e may be a gradua l improvem ent in reversibl e
TO in th e abse nce of an agent th at promot es TO. There m ay also exist a specific thera peu tic
effect in which clozapine ac tively reduces symptoms of T O. T his patient 's rapid respon se
suggests tha t she ben efit ed from a n acu te suppressive effec t ; how ever, either of th e two
re maining mech anism s may st ill account for patient 's lon g term improvement wit h clozapine.
Dat a from clinical tri als sugges t th at approximately 43% of patients wit h T O , particularly
th ose with dyst oni c featu res, show im provement (50% or greater reduct ion in TO sympto ms)
after t rea tme n t with clozapine.
C ur re nt ly, no sa t isfacto ry t reatment ex ists for irr eversibl e ta rdive dys kinesia , a ltho ug h
some cases do appear to be reversible if detected ea rly enoug h. Therefore, cur re nt treat ment is
focuse d on prevention , th e ph ysician havin g an obliga tion to decr ease th e dosage of neurolept ic
th erapy without compromising psychi atric benefit. For th ose pa tien ts who do develop TD,
severa l t he ra pe u tic s tra tegies have been proposed, but have subsequent ly pr oved to be
disappoint ing ( I) . Reducti on or di scont inu ation of neurol ept ic therapy is usually recom -
mended , but difficult du e to br eakthrou gh of psychi atric symptoms ( 1,2); prolonged th er apy
usu ally aggravates TO to th e point wh er e it may even tually become life-threa tening for th e
pa ti ent.
Perhaps a ll pat ients ca pa ble of tolerating clozapine, who show pr ob abl e or d efinite signs of
TO, sho uld ro ut inely receive a tri al of clozapine. Serious side effects ma y cont ribute to a
ph ysicians re luc ta nce to initiat e clozapine the rapy with such patients ; how ever, rout ine
66 J EFFERSON JO URNAL OF PSYCHIATRY
hemat ologic monitoring has virtuall y eliminat ed fata liti es associa ted with ag ra nulocytos is.
Mor eover , in th e absence of an ade q ua te t re a tme nt for 'I'D , patient s are ofte n ca ug ht in an
un fortunat e cli nica l situa tio n in which bo th decr eas es an d incr eases in neu rol eptic ther a py
aggravate 'I'D in th e sho rt a nd long term, res pec t ively. \ Vith con t inue d use a nd increases in
patient rep orting, clozapine may eme rge as th e go ld sta ndard in neuroleptic th erap y for th e
pr evention and/ or tr eatment of 'I'D .
Kerry nl. Kall as, },[S3
Universi ty of Minnesota Med ical School
Dean K. Knudson, nl. D.
Minneapolis Psychi atr ic Inst it ute
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